All In Biotech

Drug Trial Radar · NCT02092116

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF and HIV-1 Reactivation Using Romidepsin on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART

Last checked: Nov 19, 2026Latest source record: Mar 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

26

Actual

Start

Mar 2014

Primary completion

Aug 2015

Study completion Dec 2015

Sponsor

Lead sponsor
Bionor Immuno ASIndustry
Sponsor type
Industry
Collaborators
Celgene Corporation
First posted
Mar 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The REDUC trial's objective is to address one of the core issues with the treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs. The reservoirs are unaffected by conventional HIV medication and invisible to the immune system. HDACi have the potential to activate these latently infected cells. This will make the HIV infected cells visible to the immune system; the immune response generate by Vacc-4x will be able to attack and eliminate the infected cells.

Conditions

  • HIV I Infection

Interventions

  • RomidepsinDrug

    Latency reversing agent

  • Vacc-4xBiological

    Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

  • rhuGM-CSFBiological

    Granulocyte macrophage colony stimulating factor as a local adjuvant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: 3 weeks
  2. Part B: Changes From Baseline in HIV-1 Reservoir (Total HIV-1DNA; Integrated HIV-1 DNA in Unfractionated CD4+ T Cells and Replication Competent Provirus.Time frame: Day 161/175

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aarhus University Hospital, Skejby Sygehus

    Aarhus N, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.